- (2024): Hamidi S+, Thyroid Dec, Online ahead of print39%
Adverse reactions attributed to entire drug class 'RET (Rearranged during Transfection) kinase inhibitor'
Please login to view adverse reactions.
- (2025): Riya IJ+, Endocr Relat Cancer May, Online ahead of print16% (≥ grade 3) [REVIEW]
- (2024): Hamidi S+, Thyroid Dec, Online ahead of print26%
QT interval prolonged / QT prolongation
- (2024): Hamidi S+, Thyroid Dec, Online ahead of print39%
Alanine aminotransferase (ALT) increased
- (2025): Riya IJ+, Endocr Relat Cancer May, Online ahead of print11% (≥ grade 3) [REVIEW]
- (2024): Hamidi S+, Thyroid Dec, Online ahead of print48%
Aspartate aminotransferase (AST) increased
- (2025): Riya IJ+, Endocr Relat Cancer May, Online ahead of print6% (≥ grade 3) [REVIEW]
- (2024): Hamidi S+, Thyroid Dec, Online ahead of print26%
- (2025): Meng Z+, Clin Epidemiol 17, 87-104 [REVIEW] (association) (pharmacovigilance / pharmacoepidemiology)
- (2025): Riya IJ+, Endocr Relat Cancer May, Online ahead of print3% (≥ grade 3) [REVIEW]
- (2023): Ke JY+, Invest New Drugs Aug, Online ahead of print13% (grade 3–4) [REVIEW]
Neutropenia (neutrophils decreased)
- (2023): Ke JY+, Invest New Drugs Aug, Online ahead of print13% (grade 3–4) [REVIEW]
- (2024): Hamidi S+, Thyroid Dec, Online ahead of print35%
